According to Gram Research analysis, two diabetes medications—semaglutide and linagliptin—changed how damaged heart cells produce energy in a pig study. Both drugs reduced fatty acid burning and increased glucose use in oxygen-starved heart tissue, with semaglutide showing stronger effects. This metabolic shift could potentially protect hearts damaged by blocked arteries, though human studies are needed to confirm benefits.
Researchers studied two diabetes medications—semaglutide and linagliptin—to see if they could help hearts damaged by blocked arteries and metabolic syndrome. Using pigs with similar heart problems to humans, they found that both drugs changed how heart muscle cells use energy. Instead of burning fat for fuel, the treated hearts switched to using more glucose (sugar). This metabolic shift could potentially protect damaged heart tissue, though more research in humans is needed to confirm these benefits.
Key Statistics
A 2026 animal study published in Surgery found that semaglutide treatment reduced fatty acid oxidation and increased glucose metabolism in heart tissue of pigs with both coronary artery disease and metabolic syndrome.
In the same 2026 study of 24 pigs, linagliptin produced similar but less pronounced metabolic changes, also reducing fatty acid oxidation while increasing glucose metabolism in damaged heart regions.
Both medications increased citrate cycle activity in the most oxygen-starved regions of the heart, suggesting enhanced energy production in the areas most vulnerable to damage from blocked arteries.
The Quick Take
- What they studied: Whether two diabetes medications (semaglutide and linagliptin) change how heart muscle cells produce energy when the heart is damaged by blocked arteries
- Who participated: 24 pigs divided into three groups: 8 receiving semaglutide, 8 receiving linagliptin, and 8 receiving no medication. All pigs were fed a high-fat diet and had surgically created blocked arteries to mimic human heart disease
- Key finding: Both medications reduced how much the heart burns fat for energy and increased how much it uses glucose instead. Semaglutide showed stronger effects than linagliptin
- What it means for you: These findings suggest these diabetes drugs might protect damaged hearts by changing their fuel source, but this is early-stage research in animals. Human studies are needed before doctors might recommend these drugs specifically for heart protection
The Research Details
Researchers created a pig model that mimics human heart disease combined with metabolic syndrome (a cluster of conditions including high blood pressure, high blood sugar, and excess body fat). They fed pigs a high-fat diet for 6 weeks, then surgically placed a device that gradually blocked one of the heart’s main arteries over 5 weeks. This mimics how human coronary artery disease develops slowly over time.
The pigs were divided into three equal groups: one received semaglutide (a GLP-1 receptor agonist used for diabetes), one received linagliptin (a DPP-4 inhibitor also used for diabetes), and one received no medication as a control. After 5 weeks of treatment, researchers removed heart tissue from the most damaged areas and analyzed it using advanced molecular techniques.
They used two complementary approaches: proteomics (studying all the proteins in the tissue) and metabolomics (studying all the chemical compounds involved in energy production). This combined analysis revealed exactly how the medications changed the heart’s metabolism at the molecular level.
This research approach is important because it bridges the gap between simple lab studies and human trials. Pigs have hearts very similar to humans in size and function, making them better models than mice or rats. By examining the actual molecular changes in damaged heart tissue, researchers could see exactly how these medications work, not just whether they help overall. This detailed understanding is crucial for developing better heart disease treatments
This is a controlled laboratory study with clear group assignments and objective molecular measurements. The use of advanced proteomics and metabolomics provides detailed, unbiased data about cellular changes. However, the study is limited to animals, and results don’t automatically apply to humans. The sample size (8 animals per group) is reasonable for this type of detailed molecular research but relatively small. The study was published in a peer-reviewed surgical journal, indicating it met scientific standards for publication
What the Results Show
Both semaglutide and linagliptin changed how the damaged heart muscle cells produce energy. The most striking change was a reduction in fatty acid oxidation—the process where heart cells burn fat for fuel. This occurred in both treatment groups, though semaglutide showed stronger effects.
Simultaneously, both medications increased glucose metabolism, meaning the heart cells switched to using more sugar for energy. This shift was accompanied by increased activity in the citrate cycle, a fundamental energy-production pathway in cells. Semaglutide also triggered increased activity in the pentose phosphate pathway and fatty acid biosynthesis, suggesting more complex metabolic remodeling.
These changes occurred specifically in the most ischemic (oxygen-starved) regions of the heart—exactly where protection would be most beneficial. The researchers confirmed these molecular findings using immunoblotting and tissue examination, ensuring the results were reliable and not artifacts of the analysis method.
Linagliptin produced a similar but less pronounced metabolic profile compared to semagluptin. While both drugs reduced fatty acid oxidation, semaglutide’s effects were more comprehensive and affected more metabolic pathways. This suggests that GLP-1 receptor agonists (like semaglutide) may have broader metabolic effects than DPP-4 inhibitors (like linagliptin), though both appear to shift the heart toward glucose metabolism. The fact that these changes occurred in pigs with both metabolic syndrome and coronary artery disease suggests the medications work in this specific high-risk population
Previous research suggested that GLP-1 receptor agonists and DPP-4 inhibitors might protect the heart beyond their blood-sugar-lowering effects, but the mechanisms were unclear. This study provides molecular evidence supporting that hypothesis. The shift from fat to glucose metabolism aligns with emerging research suggesting that damaged hearts may function better when they use glucose instead of fat. This metabolic switch has been observed in other heart disease models and may represent a protective adaptation
This research was conducted entirely in pigs, not humans, so results may not directly translate to human patients. The study examined only the molecular changes in heart tissue, not whether these changes actually improved heart function or survival. The treatment period was relatively short (5 weeks), so long-term effects are unknown. The study didn’t compare these medications to other heart-protective treatments, so we can’t say whether they’re better or worse than existing options. Finally, all animals were on a high-fat diet, so results may not apply to people with normal diets
The Bottom Line
Based on this animal research, these medications show promise for protecting damaged hearts through metabolic changes, but human evidence is still needed. Current recommendations remain unchanged: these medications are approved for diabetes management and may have heart benefits, but they shouldn’t be used solely for heart protection outside of diabetes treatment. If you have both diabetes and heart disease, discuss with your doctor whether these medications are appropriate for you. Confidence level: Low to Moderate (animal study only)
This research is most relevant to people with both type 2 diabetes and coronary artery disease, as well as those with metabolic syndrome. Cardiologists and endocrinologists should note these findings as they consider treatment options. People without diabetes should not assume these medications will protect their hearts. Those with heart disease but normal blood sugar should wait for human studies before considering these drugs
In this animal study, metabolic changes were visible after 5 weeks of treatment. In humans, if similar changes occur, they might take weeks to months to develop. Any actual improvement in heart function would likely take longer to measure. Don’t expect immediate benefits; any protective effects would likely accumulate over months to years of treatment
Frequently Asked Questions
Can semaglutide or linagliptin protect your heart if you have blocked arteries?
This animal study suggests they may help by changing how heart cells use energy, but human evidence is still needed. These medications are currently approved for diabetes, not heart disease prevention. Talk to your cardiologist about whether they’re appropriate for your specific situation.
What does it mean when a heart switches from burning fat to using glucose for energy?
The heart normally uses both fat and glucose for fuel. Damaged hearts may function better using glucose because it requires less oxygen to produce energy. This metabolic switch could reduce stress on oxygen-starved tissue, potentially protecting it from further damage.
Is semaglutide better than linagliptin for heart protection based on this research?
This study shows semaglutide produced stronger metabolic changes than linagliptin in pig hearts. However, both medications showed similar directional effects. More research is needed to determine if these differences matter for actual heart protection in humans.
Should I ask my doctor about these medications if I have heart disease but not diabetes?
Not based on this research alone. These medications are approved for diabetes management. While they show promise for heart protection, human studies haven’t yet proven they benefit non-diabetic patients with heart disease. Wait for human clinical trials before considering them for heart protection alone.
How long would it take to see heart benefits from these medications?
Unknown in humans. This animal study showed metabolic changes after 5 weeks, but actual improvements in heart function would likely take longer. Any benefits would probably develop over months to years of consistent treatment, not days or weeks.
Want to Apply This Research?
- If taking semaglutide or linagliptin, track your energy levels, exercise tolerance, and any chest discomfort weekly. Note any changes in shortness of breath during normal activities, as improved heart metabolism might enhance exercise capacity over time
- Combine medication use with heart-healthy behaviors: maintain a balanced diet (lower in saturated fat), engage in regular moderate exercise as approved by your doctor, and monitor blood sugar levels consistently. These actions work synergistically with the metabolic changes these medications may produce
- Work with your healthcare team to monitor heart function through regular check-ups and tests (like EKGs or stress tests if appropriate). Track blood sugar control, blood pressure, and cholesterol levels monthly. Report any new symptoms like unusual fatigue or chest discomfort immediately
This research was conducted in animals and has not been tested in humans. These findings do not establish that semaglutide or linagliptin should be used to treat or prevent heart disease outside of their approved use for type 2 diabetes management. Do not start, stop, or change any medications based on this research without consulting your healthcare provider. If you have heart disease or metabolic syndrome, work with your cardiologist and primary care physician to develop an appropriate treatment plan based on established clinical evidence and your individual health needs.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.